{
  "emaEpar": [
    {
      "activeSubstance": "trastuzumab",
      "conditionIndication": "Breast cancerMetastatic breast cancerHerzuma is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC):as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments.in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable.in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease.in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab.Early breast cancerHerzuma is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC):following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable).following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel.in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.in combination with neoadjuvant chemotherapy followed by adjuvant Herzuma therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter.Herzuma should only be used in patients with metastatic or early breast cancer whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.Metastatic gastric cancer Herzuma in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease.Herzuma should only be used in patients with metastatic gastric cancer (MGC) whose tumours have HER2 overexpression as defined by IHC2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result. Accurate and validated assay methods should be used.",
      "inn": "trastuzumab",
      "marketingAuthorisationDate": "2018-02-08 01:00:00",
      "marketingAuthorisationHolder": "Celltrion Healthcare Hungary Kft.",
      "medicineName": "Herzuma",
      "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/herzuma"
    },
    {
      "activeSubstance": "trastuzumab",
      "conditionIndication": "Metastatic breast cancerKanjinti is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC):as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone-receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments.in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable.in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease.in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab.Early breast cancerKanjinti is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC):following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable).following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel.in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.in combination with neoadjuvant chemotherapy followed by adjuvant KANJINTI therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter.Kanjinti should only be used in patients with metastatic or early breast cancer whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.Metastatic gastric cancerKanjinti in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.Kanjinti should only be used in patients with metastatic gastric cancer (MGC) whose tumours have HER2 overexpression as defined by IHC 2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result. Accurate and validated assay methods should be used.",
      "inn": "trastuzumab",
      "marketingAuthorisationDate": "2018-05-16 00:00:00",
      "marketingAuthorisationHolder": "Amgen Europe B.V.",
      "medicineName": "Kanjinti",
      "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/kanjinti"
    },
    {
      "activeSubstance": "trastuzumab",
      "conditionIndication": "Breast cancerMetastatic breast cancerOntruzant is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC):as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments.in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable.in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease.in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab.Early breast cancerOntruzant is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC)following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable).following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel.in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.in combination with neoadjuvant chemotherapy followed by adjuvant Ontruzant therapy, for locally advanced (including inflammatory) disease or tumours >2 cm in diameter.Ontruzant should only be used in patients with metastatic or early breast cancer whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.Metastatic gastric cancerOntruzant in combination with capecitabine or 5\u2011fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.Ontruzant should only be used in patients with metastatic gastric cancer (MGC) whose tumours have HER2 overexpression as defined by IHC2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result. Accurate and validated assay methods should be used.",
      "inn": "trastuzumab",
      "marketingAuthorisationDate": "2017-11-15 01:00:00",
      "marketingAuthorisationHolder": "Samsung Bioepis NL B.V.",
      "medicineName": "Ontruzant",
      "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/ontruzant"
    },
    {
      "activeSubstance": "trastuzumab",
      "conditionIndication": "Breast cancerMetastatic breast cancer Zercepac is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC):as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable.in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease.in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab.Early breast cancer Zercepac is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC).following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable).following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel.in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.in combination with neoadjuvant chemotherapy followed by adjuvant Zercepac therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter.Zercepac should only be used in patients with metastatic or early breast cancer whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.Metastatic gastric cancer Zercepac in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.Zercepac should only be used in patients with metastatic gastric cancer (MGC) whose tumours have HER2 overexpression as defined by IHC2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result. Accurate and validated assay methods should be used.",
      "inn": "trastuzumab",
      "marketingAuthorisationDate": "2020-07-27 00:00:00",
      "marketingAuthorisationHolder": "Accord Healthcare S.L.U.",
      "medicineName": "Zercepac",
      "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zercepac"
    },
    {
      "activeSubstance": "trastuzumab",
      "conditionIndication": "Breast cancerMetastatic breast cancerOgivri is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC):as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatmentsin combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitablein combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic diseasein combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab.Early breast cancer\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Ogivri is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC):following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable)following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxelin combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.in combination with neoadjuvant chemotherapy followed by adjuvant Ogivri therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter.Ogivri should only be used in patients with metastatic or EBC whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.Metastatic gastric cancerOgivri in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.Ogivri should only be used in patients with metastatic gastric cancer (MGC) whose tumours have HER2 overexpression as defined by IHC2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result. Accurate and validated assay methods should be used.",
      "inn": "trastuzumab",
      "marketingAuthorisationDate": "2018-12-12 01:00:00",
      "marketingAuthorisationHolder": "Mylan S.A.S",
      "medicineName": "Ogivri",
      "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/ogivri"
    },
    {
      "activeSubstance": "trastuzumab",
      "conditionIndication": "Breast cancer, , Metastatic breast cancer, , Herceptin is indicated for the treatment of patients with HER2-positive metastatic breast cancer:, , as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone-receptor-positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments;, \tin combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable;, \tin combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease;, \tin combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor-positive metastatic breast cancer, not previously treated with trastuzumab., Early breast cancer, , Herceptin is indicated for the treatment of patients with HER2-positive early breast cancer:, , following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable);, \tfollowing adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel;, \tin combination with adjuvant chemotherapy consisting of docetaxel and carboplatin;, \tin combination with neoadjuvant chemotherapy followed by adjuvant Herceptin therapy, for locally advanced (including inflammatory) disease or tumours >2 cm in diameter., Herceptin should only be used in patients with metastatic or early breast cancer whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay., , Metastatic gastric cancer, , Herceptin in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach or gastroesophageal junction who have not received prior anticancer treatment for their metastatic disease., , Herceptin should only be used in patients with metastatic gastric cancer whose tumours have HER2 overexpression as defined by IHC2+ and a confirmatory SISH or FISH result, or by an IHC3+ result. Accurate and validated assay methods should be used., ",
      "inn": "trastuzumab",
      "marketingAuthorisationDate": "2000-08-28 00:00:00",
      "marketingAuthorisationHolder": "Roche Registration GmbH",
      "medicineName": "Herceptin",
      "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/herceptin"
    },
    {
      "activeSubstance": "trastuzumab",
      "conditionIndication": "Breast cancerMetastatic breast cancerTrazimera is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer: (MBC):as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments.in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable.in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease.in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab.Early breast cancerTrazimera is indicated for the treatment of adult patients with HER2 positive early breast cancer. (EBC).following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable).following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel.in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.in combination with neoadjuvant chemotherapy followed by adjuvant Trazimera therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter.Trazimera should only be used in patients with metastatic or early breast cancer whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.Metastatic gastric cancerTrazimera in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.Trazimera should only be used in patients with metastatic gastric cancer (MGC) whose tumours have HER2 overexpression as defined by IHC2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result. Accurate and validated assay methods should be used.",
      "inn": "trastuzumab",
      "marketingAuthorisationDate": "2018-07-26 00:00:00",
      "marketingAuthorisationHolder": "Pfizer Europe MA EEIG",
      "medicineName": "Trazimera",
      "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/trazimera"
    }
  ],
  "fdaDrugLabel": [
    {
      "brand": "Phesgo",
      "indication": "1 INDICATIONS AND USAGE PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for: Use in combination with chemotherapy as: neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. ( 1.1 ) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence ( 1.1 ) Use in combination with docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. ( 1.2 ) 1.1 Early Breast Cancer (EBC) PHESGO is indicated for use in combination with chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer [see Dosage and Administration (2.2) and Clinical Studies (14.2) ] . the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence [see Dosage and Administration (2.2) and Clinical Studies (14.2) ] . Select patients for therapy based on an FDA-approved companion diagnostic test [see Dosage and Administration (2.1) ]. 1.2 Metastatic Breast Cancer (MBC) PHESGO is indicated for use in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease [see Dosage and Administration (2.2) and Clinical Studies (14.1) ] . Select patients for therapy based on an FDA-approved companion diagnostic test [see Dosage and Administration (2.1) ].",
      "manufacturer": "Genentech, Inc.",
      "splSetId": "27dd5e6b-72cd-458d-a015-cf4dab5800da"
    },
    {
      "brand": "Herceptin",
      "indication": "1 INDICATIONS AND USAGE Herceptin is a HER2/neu receptor antagonist indicated for: The treatment of HER2-overexpressing breast cancer. ( 1.1 , 1.2 ) The treatment of HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. ( 1.3 ) Select patients for therapy based on an FDA-approved companion diagnostic for Herceptin ( 1 , 2.1 ). 1.1 Adjuvant Breast Cancer Herceptin is indicated for adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature [see Clinical Studies ( 14.1 )] ) breast cancer as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel as part of a treatment regimen with docetaxel and carboplatin as a single agent following multi-modality anthracycline based therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Herceptin [see Dosage and Administration (2.1) ] . 1.2 Metastatic Breast Cancer Herceptin is indicated: In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease. Select patients for therapy based on an FDA-approved companion diagnostic for Herceptin [see Dosage and Administration (2.1) ] . 1.3 Metastatic Gastric Cancer Herceptin is indicated, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease. Select patients for therapy based on an FDA-approved companion diagnostic for Herceptin [see Dosage and Administration (2.1) ] .",
      "manufacturer": "Genentech, Inc.",
      "splSetId": "492dbdb2-077e-4064-bff3-372d6af0a7a2"
    },
    {
      "brand": "OGIVRI",
      "indication": "1 INDICATIONS AND USAGE Ogivri is a HER2/neu receptor antagonist indicated for: \u2022 The treatment of HER2-overexpressing breast cancer. ( 1.1 , 1.2 ) \u2022 The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. ( 1.3 ) Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product ( 1 , 2.1 ). 1.1 Adjuvant Breast Cancer Ogivri is indicated for adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature [see Clinical Studies (14.1) ] ) breast cancer \u2022 as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel \u2022 as part of a treatment regimen with docetaxel and carboplatin \u2022 as a single agent following multi-modality anthracycline based therapy. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.1) ]. 1.2 Metastatic Breast Cancer Ogivri is indicated: \u2022 In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer \u2022 As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.1) ]. 1.3 Metastatic Gastric Cancer Ogivri is indicated, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.1) ] .",
      "manufacturer": "Mylan Institutional LLC",
      "splSetId": "6b7938e6-14c7-4a65-9605-967542ecfb8f"
    },
    {
      "brand": "Kanjinti",
      "indication": "1 INDICATIONS AND USAGE KANJINTI is a HER2/neu receptor antagonist indicated for: the treatment of HER2 overexpressing breast cancer. ( 1.1 , 1.2 ) the treatment of HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. ( 1.3 ) Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product ( 1 , 2.1 ). 1.1 Adjuvant Breast Cancer KANJINTI is indicated for adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature [see Clinical Studies ( 14.1 )] ) breast cancer as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel as part of a treatment regimen with docetaxel and carboplatin as a single agent following multi-modality anthracycline based therapy. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [ see Dosage and Administration ( 2.1 ) ] . 1.2 Metastatic Breast Cancer KANJINTI is indicated: In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration ( 2.1 )] 1.3 Metastatic Gastric Cancer KANJINTI is indicated, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration ( 2.1 )] .",
      "manufacturer": "Amgen Inc",
      "splSetId": "9a94f5b2-b84e-4987-8ea1-c4346db5a5fa"
    },
    {
      "brand": "Ontruzant",
      "indication": "1 INDICATIONS AND USAGE Ontruzant is a HER2/neu receptor antagonist indicated for: The treatment of HER2-overexpressing breast cancer. ( 1.1 , 1.2 ) The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. ( 1.3 ) Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product ( 1 , 2.1 ). 1.1 Adjuvant Breast Cancer Ontruzant is indicated for adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature [see Clinical Studies ( 14.1 )] ) breast cancer as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel as part of a treatment regimen with docetaxel and carboplatin as a single agent following multi-modality anthracycline based therapy. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration ( 2.1 )] . 1.2 Metastatic Breast Cancer Ontruzant is indicated: In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration ( 2.1 )] . 1.3 Metastatic Gastric Cancer Ontruzant is indicated, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration ( 2.1 )] .",
      "manufacturer": "Merck Sharp & Dohme Corp.",
      "splSetId": "a8d34591-b709-492b-84e3-d7764db9366a"
    },
    {
      "brand": "HERZUMA",
      "indication": "1 INDICATIONS AND USAGE HERZUMA is a HER2/neu receptor antagonist indicated for: the treatment of HER2-overexpressing breast cancer. ( 1.1 , 1.2 ) the treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. ( 1.3 ) Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product. ( 1 , 2.1 ) 1.1 Adjuvant Breast Cancer HERZUMA is indicated for adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature [see Clinical Studies (14.1) ] ) breast cancer as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel as part of a treatment regimen with docetaxel and carboplatin as a single agent following multi-modality anthracycline based therapy. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.1) ] . 1.2 Metastatic Breast Cancer HERZUMA is indicated: In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.1) ] . 1.3 Metastatic Gastric Cancer HERZUMA is indicated, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.1) ] .",
      "manufacturer": "Cephalon, Inc.",
      "splSetId": "ae71c003-883a-4cd8-ad50-e8cc9a54e971"
    },
    {
      "brand": "Trazimera",
      "indication": "1 INDICATIONS AND USAGE TRAZIMERA is a HER2/neu receptor antagonist indicated for: The treatment of HER2-overexpressing breast cancer. ( 1.1 , 1.2 ) The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. ( 1.3 ) Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product ( 1 , 2.1 ). 1.1 Adjuvant Breast Cancer TRAZIMERA is indicated for adjuvant treatment of HER2-overexpressing node positive or node negative (ER/PR negative or with one high risk feature [see Clinical Studies (14.1) ] ) breast cancer as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel as part of a treatment regimen with docetaxel and carboplatin as a single agent following multi-modality anthracycline based therapy. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.1) ] . 1.2 Metastatic Breast Cancer TRAZIMERA is indicated: In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.1) ]. 1.3 Metastatic Gastric Cancer TRAZIMERA is indicated, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.1) ] .",
      "manufacturer": "Pfizer Laboratories Div Pfizer Inc",
      "splSetId": "b9c5e894-27d2-4245-a653-df986fed3c56"
    },
    {
      "brand": "Herceptin Hylecta",
      "indication": "1 INDICATIONS AND USAGE HERCEPTIN HYLECTA is a combination of trastuzumab, a HER2/neu receptor antagonist, and hyaluronidase, an endoglycosidase, indicated in adults for: The treatment of HER2-overexpressing breast cancer. ( 1.1 , 1.2 ) Select patients for therapy based on an FDA-approved companion diagnostic for trastuzumab. ( 1 , 2.1 ) 1.1 Adjuvant Breast Cancer HERCEPTIN HYLECTA is indicated for adjuvant treatment of adults with HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature [see Clinical Studies (14.1) ] ) breast cancer: as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel as part of a treatment regimen with docetaxel and carboplatin as a single agent following multi-modality anthracycline based therapy. Select patients for therapy based on an FDA-approved companion diagnostic for trastuzumab [see Dosage and Administration (2.1) ] . 1.2 Metastatic Breast Cancer HERCEPTIN HYLECTA is indicated in adults: In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease. Select patients for therapy based on an FDA-approved companion diagnostic for trastuzumab [see Dosage and Administration (2.1) ] .",
      "manufacturer": "Genentech, Inc.",
      "splSetId": "ebf30894-41cf-480c-8bc3-56f592a13813"
    }
  ],
  "id": "Trastuzumab",
  "nciThesaurus": {
    "casRegistry": "180288-69-1",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas.",
    "fdaUniiCode": "P188ANX8CK",
    "identifier": "C1647",
    "preferredName": "Trastuzumab",
    "semanticType": "Amino Acid, Peptide, or Protein",
    "subclassOf": [
      "C155711"
    ],
    "synonyms": [
      "ABP 980",
      "ALT02",
      "Anti-ERB-2",
      "Anti-HER2/c-erbB2 Monoclonal Antibody",
      "Anti-c-ERB-2",
      "Anti-c-erbB2 Monoclonal Antibody",
      "Anti-erbB-2",
      "Anti-erbB2 Monoclonal Antibody",
      "Anti-p185-HER2",
      "HER2 Monoclonal Antibody",
      "Herceptin",
      "Herceptin Biosimilar PF-05280014",
      "Herceptin Trastuzumab Biosimilar PF-05280014",
      "Herzuma",
      "Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman p185(Sup c-erbB2) Receptor), Disulfide with Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer",
      "Kanjinti",
      "MoAb HER2",
      "Monoclonal Antibody HER2",
      "Monoclonal Antibody c-erb-2",
      "Ogivri",
      "Ontruzant",
      "PF-05280014",
      "RO0452317",
      "SB3",
      "TRASTUZUMAB",
      "Trastuzumab",
      "Trastuzumab Biosimilar ABP 980",
      "Trastuzumab Biosimilar ALT02",
      "Trastuzumab Biosimilar HLX02",
      "Trastuzumab Biosimilar PF-05280014",
      "Trastuzumab Biosimilar SB3",
      "Trastuzumab Biosimilar SIBP-01",
      "Trastuzumab-anns",
      "Trastuzumab-dkst",
      "Trastuzumab-dttb",
      "Trastuzumab-pkrb",
      "Trastuzumab-qyyp",
      "Trazimera",
      "c-erb-2 Monoclonal Antibody",
      "rhuMAb HER2",
      "trastuzumab",
      "trastuzumab biosimilar EG12014"
    ]
  }
}